Human Genome Epidemiology Literature Finder
Records 1 - 25 (of 25 Records) |
Query Trace: Fatigue and KRAS[original query] |
---|
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Oct 28 (30): 4609-15. Johnson Faye M, Bekele B Nebiyou, Feng Lei, Wistuba Ignacio, Tang Xi Ming, Tran Hai T, Erasmus Jeremy J, Hwang Li-Ling, Takebe Naoko, Blumenschein George R, Lippman Scott M, Stewart David |
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Jun 16 (11): 3078-87. Lind Joline S W, Dingemans Anne-Marie C, Groen Harry J M, Thunnissen Frederik B, Bekers Otto, Heideman Daniëlle A M, Honeywell Richard J, Giovannetti Elisa, Peters Godefridus J, Postmus Pieter E, van Suylen Robert Jan, Smit Egbert |
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011 Aug 6 (8): 1435-7. Riely Gregory J, Johnson Melissa L, Medina Chanoa, Rizvi Naiyer A, Miller Vincent A, Kris Mark G, Pietanza M Catherine, Azzoli Christopher G, Krug Lee M, Pao William, Ginsberg Michelle |
Overall and KRAS-specific results of combined cetuximab treatment and chemotherapy for metastatic colorectal cancer: a meta-analysis. International journal of colorectal disease 2011 Aug 26 (8): 1025-33. Zhang Linlin, Ma Li, Zhou Qingh |
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 May 30 (13): 1505-12. Weickhardt Andrew J, Price Tim J, Chong Geoff, Gebski Val, Pavlakis Nick, Johns Terrance G, Azad Arun, Skrinos Effie, Fluck Kate, Dobrovic Alexander, Salemi Renato, Scott Andrew M, Mariadason John M, Tebbutt Niall |
Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2013 Jan 23 (1): 73-80. Steffensen Karina Dahl, Waldstrøm Marianne, Pallisgård Niels, Lund Bente, Bergfeldt Kjell, Wihl Jessica, Keldsen Nina, Marth Christian, Vergote Ignace, Jakobsen Ande |
A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). Lung cancer (Amsterdam, Netherlands) 2012 Dec . Kim SH, Shim HS, Cho J, Jeong JH, Kim SM, Hong YK, Sung JH, Ha SJ, Kim HR, Chang H, Kim JH, Tania C, Cho BC |
Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. European journal of cancer (Oxford, England : 1990) 2013 Sep 49 (13): 13. Richards D, Kocs DM, Spira AI, David McCollum A, Diab S, Hecker LI, Cohn A, Zhan F, Asmar L |
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Jun 19 (11): 3068-77. Socinski Mark A, Goldman Jonathan, El-Hariry Iman, Koczywas Marianna, Vukovic Vojo, Horn Leora, Paschold Eugene, Salgia Ravi, West Howard, Sequist Lecia V, Bonomi Philip, Brahmer Julie, Chen Lin-Chi, Sandler Alan, Belani Chandra P, Webb Timothy, Harper Harry, Huberman Mark, Ramalingam Suresh, Wong Kwok-Kin, Teofilovici Florentina, Guo Wei, Shapiro Geoffrey |
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC cancer 2016 16 412. Adenis Antoine, de la Fouchardiere Christelle, Paule Bernard, Burtin Pascal, Tougeron David, Wallet Jennifer, Dourthe Louis-Marie, Etienne Pierre-Luc, Mineur Laurent, Clisant Stéphanie, Phelip Jean-Marc, Kramar Andrew, Andre Thier |
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Mar . Pietanza Catherine M, Hellmann Matthew D, Fiore John J, Smith-Marrone Stephanie, Basch Ethan M, Schwartz Lawrence H, Ginsberg Michelle S, Shouery Marwan, Newman Samantha K, Shaw Mary, Rogak Lauren J, Lash Alex, Hilden Patrick, Kris Mark |
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Targeted oncology 2016 Dec . Van Laethem Jean-Luc, Riess Hanno, Jassem Jacek, Haas Michael, Martens Uwe M, Weekes Colin, Peeters Marc, Ross Paul, Bridgewater John, Melichar Bohuslav, Cascinu Stefano, Saramak Piotr, Michl Patrick, Van Brummelen David, Zaniboni Alberto, Schmiegel Wollf, Dueland Svein, Giurescu Marius, Garosi Vittorio L, Roth Katrin, Schulz Anke, Seidel Henrik, Rajagopalan Prabhu, Teufel Michael, Childs Barrett |
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2015 Dec 10 (12): 1745-53. Paz-Ares Luis, Hirsh Vera, Zhang Li, de Marinis Filippo, Yang James Chih-Hsin, Wakelee Heather A, Seto Takashi, Wu Yi-Long, Novello Silvia, Juhász Erszébet, Arén Osvaldo, Sun Yan, Schmelter Thomas, Ong Teng Jin, Peña Carol, Smit Egbert F, Mok Tony |
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. ESMO open 2016 1 (6): e000086. Martinelli E, Cardone C, Troiani T, Normanno N, Pisconti S, Sforza V, Bordonaro A R, Rachiglio A M, Lambiase M, Latiano T P, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E, Ciardiello F, Iaffaioli Vincenzo, Nasti Guglielmo, Nappi Anna, Botti Gerardo, Tatangelo F, Chicchinelli Nicoletta, Montrone Mirko, Sebastio Annamaria, Guarino Tiziana, Simone Gianni, Graziano Paolo, Chiarazzo Cinzia, Maggio GabrieleDi, Longhitano Laura, Manusia Mario, Cartenì Giacomo, Nappi Oscar, Micheli Pietro, Leo Luigi, Rossi Sabrina, Cassano Alessandra, Tommaselli Eugenio, Giordano Guido, Sponziello Francesco, Marino Antonella, Rinaldi Antonio, Romito Sante, Muda Andrea Onetti, Lorusso Vito, Leo Silvana, Barni Sandro, Grimaldi Giuseppe, Aieta Miche |
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. British journal of cancer 2017 Feb . Bendell Johanna C, Javle Milind, Bekaii-Saab Tanios S, Finn Richard S, Wainberg Zev A, Laheru Daniel A, Weekes Colin D, Tan Benjamin R, Khan Gazala N, Zalupski Mark M, Infante Jeffrey R, Jones Suzanne, Papadopoulos Kyriakos P, Tolcher Anthony W, Chavira Renae E, Christy-Bittel Janna L, Barrett Emma, Patnaik Ami |
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. Oncotarget 2017 Sep 8 (41): 69651-69662. Leighl Natasha B, Tsao Ming-Sound, Liu Geoffrey, Tu Dongsheng, Ho Cheryl, Shepherd Frances A, Murray Nevin, Goffin John R, Nicholas Garth, Sakashita Shingo, Chen Zhuo, Kim Lucia, Powers Jean, Seymour Lesley, Goss Glenwood, Bradbury Penelope |
Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. Cancer science 2018 Jun . Osumi Hiroki, Shinozaki Eiji, Mashima Tetsuo, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Ota Yumiko, Nakayama Izuma, Takahari Daisuke, Chin Keisho, Miki Yoshio, Yamaguchi Kens |
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2018 Mar 117 44-49. Gerber David E, Socinski Mark A, Neal Joel W, Wakelee Heather A, Shirai Keisuke, Sequist Lecia V, Rosovsky Rachel P, Lilenbaum Rogerio C, Bastos Bruno R, Huang Chao, Johnson Melissa L, Hesketh Paul J, Subramaniam Deepa S, Dietrich Martin F, Chai Feng, Wang Yunxia, Kazakin Julia, Schwartz Brian, Schiller Joan H, Brahmer Julie R, Kelly Ronan |
[Characteristics of a patient with myeloid neoplasm and co-existence of t(7;11)(p15;p15) and t(5;12)(q33;p13) translocations]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2019 3 36 (3): 249-252. Zhang Xiuwen, Zhou Min, Chao Hongying, Jiang Naike, Lu Xuzhang, Jiang Yu, Zhang |
Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status. International journal of cancer 2020 12 . Jensen Benny Vittrup, Schou Jakob V, Yilmaz Mette, Johannesen Helle H, Skougaard Kristin, Linnemann Dorte, Hogdall Estrid V, Larsen Finn O, Johansen Julia S, Pfeiffer Per, Nielsen Dorte |
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Jan . Dhani Neesha C, Hirte Hal W, Wang Lisa, Burnier Julia V, Jain Angela, Butler Marcus O, Welch Stephen, Fleming Gini F, Hurteau Jean, Matsuo Koji, Matei Daniela, Jimenez Waldo, Johnston Carolyn, Cristea Mihaela, Tonkin Katia, Ghatage Prafull, Lheureux Stephanie, Mehta Anjali, Quintos Judy, Tan Qian, Kamel-Reid Suzanne, Ludkovski Olga, Tsao Ming-Sound, Wright John J, Oza Amit |
Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO precision oncology 2022 2 6 e2100424. Krop Ian E, Jegede Opeyemi A, Grilley-Olson Juneko E, Lauring Josh D, Mitchell Edith P, Zwiebel James A, Gray Robert J, Wang Victoria, McShane Lisa M, Rubinstein Larry V, Patton David, Williams P Mickey, Hamilton Stanley R, Kono Scott A, Ford James M, Garcia Agustin A, Sui Xingwei D, Siegel Robert D, Slomovitz Brian M, Conley Barbara A, Arteaga Carlos L, Harris Lyndsay N, O'Dwyer Peter J, Chen Alice P, Flaherty Keith |
RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer. Biomedicines 2023 5 11 (5): . Anna Koumarianou, Anastasios Ntavatzikos, David Symeonidis, Christos Vallilas, Maria Giannakakou, Georgios Papaxoinis, Spyridon Xynogalos, Ioannis Boukovinas, Stamatina Demiri, Katerina Kampoli, Georgios Oikonomopoulos, Epaminontas Samantas, Eleni Res, Nikolaos Androulakis, Georgia Vourli, Ioannis Souglakos, Michalis Karamouz |
Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042). Clinical cancer research : an official journal of the American Association for Cancer Research 2023 5 . Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, James Moon, Philip C Mack, Gregory J Gerstner, Timothy F Burns, Asma Taj, Wallace L Akerley, Konstantin H Dragnev, Noel Laudi, Mary W Redman, Jhanelle E Gray, David R Gandara, Karen Kel |
Efficacy and toxicity of drugs targeting KRAS mutation in non-small cell lung cancer: a meta-analysis. Expert review of anticancer therapy 2023 11 . Wei Luo, Jing Zhu, Wenxue Zhang, Airu Yu, Wei Zhou, Ke |
- Page last reviewed:Feb 1, 2024
- Content source: